

SANOFI INDIA LIMITED

Registered Office : 54/A, Sir Mathuradas Vasanji Road, Andheri East, Mumbai 400 093
Corporate Identity Number: L24239MH1956PLC009794
Tel no: (91-22) 28278000 Fax No: (91-22) 28370939
Website: www.sanofiindia.com Email: igrc.sil@sanofi.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2014

PART I	Rs. Million					
	Quarter ended 30.06.2014 Unaudited	Quarter ended 31.03.2014 Unaudited	Quarter ended 30.06.2013 Unaudited	Half Year ended 30.06.2014 Unaudited	Half Year ended 30.06.2013 Unaudited	Year ended 31.12.2013 (Audited)
Particulars						
1. Income from Operations						
(a) Net Sales (net of excise duty)	4,867	4,199	4,100	9,066	7,729	17,065
(b) Other Operating Income	191	250	251	441	503	1,024
Total income from Operations (net)	5,058	4,449	4,351	9,507	8,232	18,089
2. Expenditure						
(a) Cost of Materials Consumed	1,577	1,867	1,438	3,444	2,990	6,381
(b) Purchase of stock in trade	1,114	488	610	1,602	1,382	1,908
(c) Changes in inventories of finished goods, work in progress and stock in trade	(227)	(223)	(60)	(450)	(636)	(94)
(d) Employee benefits expense	705	625	624	1,330	1,188	2,421
(e) Depreciation and amortisation expense	240	240	227	480	450	923
(f) Other expenses	910	882	865	1,792	1,714	3,494
Total Expenses	4,319	3,879	3,704	8,198	7,088	15,033
3. Profit from Operations before other income, finance costs and exceptional items (1-2)	739	570	647	1,309	1,144	3,056
4. Other Income	135	215	145	350	308	579
5. Profit before finance costs and exceptional items (3+4)	874	785	792	1,659	1,452	3,635
6. Finance costs	2	2	1	4	4	4
7. Profit before tax and exceptional items (5-6)	872	783	791	1,655	1,448	3,631
8. Tax expense	297	266	279	563	492	1,233
9. Net Profit for the period before exceptional items (7-8)	575	517	512	1,092	956	2,398
10. Exceptional item (net of tax)						254
11. Net Profit for the period after exceptional items (9+10)	575	517	512	1,092	956	2,652
12. Paid-up equity share capital (Face Value of Rs. 10 per share)	230	230	230	230	230	230
13. Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year						13099
14. Earnings Per Share (EPS) before exceptional items (Rs.) (Basic and diluted EPS for the period, for the year to date and for the previous year)	24.96	22.48	22.27	47.44	41.55	104.12
15. Earnings Per Share (EPS) after exceptional items (Rs.) (Basic and diluted EPS for the period, for the year to date and for the previous year)	24.96	22.48	22.27	47.44	41.55	115.14

PART II						
	Quarter ended 30.06.2014 Unaudited	Quarter ended 31.03.2014 Unaudited	Quarter ended 30.06.2013 Unaudited	Half Year ended 30.06.2014 Unaudited	Half Year ended 30.06.2013 Unaudited	Year ended 31.12.2013 (Audited)
Particulars						
A. PARTICULARS OF SHAREHOLDING						
1. Public Shareholding						
- Number of Shares	91,21,035	91,21,035	91,21,035	91,21,035	91,21,035	91,21,035
- Percentage of Shareholding	39.60%	39.60%	39.60%	39.60%	39.60%	39.60%
2. Promoters and Promoter group Shareholding						
a) Pledged/Encumbered						
- Number of shares	NIL	NIL	NIL	NIL	NIL	NIL
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL	NIL
- Percentage of shares (as a % of total share capital of the company)	NIL	NIL	NIL	NIL	NIL	NIL
b) Non-encumbered						
- Number of shares	1,39,09,587	1,39,09,587	1,39,09,587	1,39,09,587	1,39,09,587	1,39,09,587
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of shares (as a % of total share capital of the company)	60.40%	60.40%	60.40%	60.40%	60.40%	60.40%

Particulars	3 Months ended June 30, 2014
B. INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	NIL
Received during the quarter	16
Disposed of during the quarter	16
Remaining unresolved at the end of the quarter	NIL

The Statement of Assets and Liabilities as required under clause 41(V)(h) of the Listing Agreement is as under:

Particulars	As at June 30, 2014 Unaudited	As at Dec 31, 2013 Audited
EQUITY AND LIABILITIES :		
Shareholders' funds :		
(a) Share capital	230	230
(b) Reserves & Surplus *	14,056	13,237
Sub-total - Shareholder's Funds	14,286	13,467
Non-current liabilities		
(a) Other long term liabilities	7	7
(b) Long term provisions	314	253
(c) Deferred Tax Liabilities (Net)	409	367
Sub-total - Non-current liabilities	730	627
Current liabilities		
(a) Trade Payables	1,830	1,871
(b) Other current liabilities	922	899
(c) Short-term provisions	926	1,584
Sub-total - Current liabilities	3,678	4,354
TOTAL EQUITY & LIABILITIES	18,694	18,448
ASSETS		
Non-current assets		
(a) Fixed Assets (Including Capital Work in Progress)	8,616	8,348
(b) Non current investments	2	2
(c) Long term loans and advances	652	616
(d) Other non-current assets	16	11
Sub-total - Non-current assets	9,286	8,977
Current assets		
(a) Inventories	3,347	3,400
(b) Trade receivables	1,213	1,183
(c) Cash & Bank Balances	2,876	2,644
(d) Short term loans & advances	1,915	2,191
(e) Other current assets	57	53
Sub-total - Current assets	9,408	9,471
TOTAL ASSETS	18,694	18,448

* After considering Interim Dividend

2

Notes:

1. The above Results were approved by the Board of Directors of the Company at its Meeting held on July 23, 2014.
2. In accordance with Clause 41 of the Listing Agreement with the Stock Exchanges, the Company's Statutory Auditors have conducted a 'Limited Review' of the Financial Results for the quarter ended June 30, 2014.
3. The Board of Directors has declared an Interim Dividend of Rs.10 per Equity share of Rs.10 to be paid to those Members whose names appear on the Register of Members of the Company on August 1, 2014 being the Record Date. The said dividend will be paid on August 14, 2014.
4. On 10th July 2014, in exercise of the powers delegated under para 19 of the Drugs (Price Control) Order 2013, Government has reduced the prices of some of the medicines manufactured/marketed by the Company. This will have a material negative impact on the profitability of the Company.
5. The Company has a single business segment namely 'Pharmaceutical Business'.
6. The figures for the previous periods have been re-grouped, wherever necessary.

SANOFI INDIA LIMITED



DR. SHAILESH AYYANGAR

MANAGING DIRECTOR

July 23, 2014

VS